Nanotag Biotechnologies

NanoTag Biotechnologies specializes in single-domain antibodies (sdAbs), also known as nanobodies or VHHs. Established in 2015 in the vibrant scientific hub of Göttingen, Germany, our company leverages deep expertise in biochemistry and advanced imaging techniques to effectively support academic research and pharmaceutical development. Our core mission is to provide the scientific community with high-quality nanobody-based reagents and to advance early-stage drug development through customized single-domain antibody discovery and protein production services. NanoTag’s products are designed for a broad range of applications, including various immunolabeling techniques such as IF (ICC, IHC), WB, IP, FACS, and ELISA. Our fluorophore-conjugated primary and secondary nanobodies (FluoTags® & Smart Secondaries®) are particularly well-suited for super-resolution imaging and quantitative analysis, enhancing the accuracy, reliability, and reproducibility of research outcomes. A key innovation in our portfolio is the ALFA® System, a patented technology that serves as a versatile research tool for scientists studying their proteins of interest (POI), and as a gateway to cutting-edge diagnostics and biomedical applications. NanoTag Biotechnologies is proud to have established strong collaborations with leading pharmaceutical companies worldwide and to have built extensive partnerships within the academic community. Our team of multidisciplinary scientists combines a broad range of expertise with commitment and an open, collaborative spirit, ensuring the highest level of service and value to our partners. We welcome partners who share our vision for advancing life science and biomedical research (Drug Development & Diagnostics).